CD131, also known as CSF2RB (colony-stimulating factor-2 receptor beta), IL3RB and IL5RB (IL-3/IL-5 receptor common beta), is a single pass, type I transmembrane glycoprotein of the type I cytokine receptor family, type 4 subfamily. CD131 consists of a extracellular region with 2 fibronectin type III (FN3) domains and a juxtamembrane WSXWS motif, a transmembrane domain, and a cytoplasmic tail with the box 1 motif. The WSXWS motif is necessary for proper protein folding and efficient intracellular transport and cell-surface receptor binding, while the box 1 motif is required for JAK interaction/activation. CD131 is a common beta chain of the high affinity receptor for IL-3, IL-5 and CSF to mediate their cellular responses. For example, the CSF receptor complex is composed of a cytokine-specific alpha- chain CD116 and a beta-chain CD131 that are shared with the receptors for IL-3 and IL-5. CD116 alone binds GM-CSF with low affinity, whereas CD131 does not bind GM-CSF by itself. Association with CD131 converts CD116 from a low affinity to a high affinity receptor for GMCSF. GMCSF is a hematopoietic cytokine that regulates differentiation, survival, and proliferation of colony-forming unit-granulocyte-macrophage progenitor cells. Mutations in CD131 may cause pulmonary surfactant metabolism dysfunction 5 (SMDP5).
Gene Symbol: CSF2RB; CD131; IL3RB; IL5RB; SMDP5; CDw131
NCBI Gene ID: 1439
Uniprot Entry: P32927
Construct Details: Full length human CD131/CSF2RB gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and with or without a selection marker, which can be used for both transient and stable expression in mammalian cells. It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles. Multiple choices of a stable antibiotic selection marker are available.
Vector Type: pLTC or pLTC-IRES-Marker (lentiviral expression vector containing a heterologous CMV promoter, see the vector map above)
Gene Insert Sequence:
ATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGCCTGGCAGGGG
CAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACCAGCCACATCACCTGCAGGTG
GGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACCCTCATTCGCCGGGTGAATGAGGACCTCCTG
GAGCCAGTGTCCTGTGACCTCAGTGATGACATGCCCTGGTCAGCCTGCCCCCATCCCCGCTGCGTGCCCA
GGAGATGTGTCATTCCCTGCCAGAGTTTTGTCGTCACTGACGTTGACTACTTCTCATTCCAACCAGACAG
GCCTCTGGGCACCCGGCTCACCGTCACTCTGACCCAGCATGTCCAGCCTCCTGAGCCCAGGGACCTGCAG
ATCAGCACCGACCAGGACCACTTCCTGCTGACCTGGAGTGTGGCCCTTGGGAGTCCCCAGAGCCACTGGT
TGTCCCCAGGGGATCTGGAGTTTGAGGTGGTCTACAAGCGGCTTCAGGACTCTTGGGAGGACGCAGCCAT
CCTCCTCTCCAACACCTCCCAGGCCACCCTGGGGCCAGAGCACCTCATGCCCAGCAGCACCTACGTGGCC
CGAGTACGGACCCGCCTGGCCCCAGGTTCTCGGCTCTCAGGACGTCCCAGCAAGTGGAGCCCAGAGGTTT
GCTGGGACTCCCAGCCAGGGGATGAGGCCCAGCCCCAGAACCTGGAGTGCTTCTTTGACGGGGCCGCCGT
GCTCAGCTGCTCCTGGGAGGTGAGGAAGGAGGTGGCCAGCTCGGTCTCCTTTGGCCTATTCTACAAGCCC
AGCCCAGATGCAGGGGAGGAAGAGTGCTCCCCAGTGCTGAGGGAGGGGCTCGGCAGCCTCCACACCAGGC
ACCACTGCCAGATTCCCGTGCCCGACCCCGCGACCCACGGCCAATACATCGTCTCTGTTCAGCCAAGGAG
GGCAGAGAAACACATAAAGAGCTCAGTGAACATCCAGATGGCCCCTCCATCCCTCAACGTGACCAAGGAT
GGAGACAGCTACAGCCTGCGCTGGGAAACAATGAAAATGCGATACGAACACATAGACCACACATTTGAGA
TCCAGTACAGGAAAGACACGGCCACGTGGAAGGACAGCAAGACCGAGACCCTCCAGAACGCCCACAGCAT
GGCCCTGCCAGCCCTGGAGCCCTCCACCAGGTACTGGGCCAGGGTGAGGGTCAGGACCTCCCGCACCGGC
TACAACGGGATCTGGAGCGAGTGGAGTGAGGCGCGCTCCTGGGACACCGAGTCGGTGCTGCCTATGTGGG
TGCTGGCCCTCATCGTGATCTTCCTCACCATCGCTGTGCTCCTGGCCCTCCGCTTCTGTGGCATCTACGG
GTACAGGCTGCGCAGAAAGTGGGAGGAGAAGATCCCCAACCCCAGCAAGAGCCACCTGTTCCAGAACGGG
AGCGCAGAGCTTTGGCCCCCAGGCAGCATGTCGGCCTTCACTAGCGGGAGTCCCCCACACCAGGGGCCGT
GGGGCAGCCGCTTCCCTGAGCTGGAGGGGGTGTTCCCTGTAGGATTCGGGGACAGCGAGGTGTCACCTCT
CACCATAGAGGACCCCAAGCATGTCTGTGATCCACCATCTGGGCCTGACACGACTCCAGCTGCCTCAGAT
CTACCCACAGAGCAGCCCCCCAGCCCCCAGCCAGGCCCGCCTGCCGCCTCCCACACACCTGAGAAACAGG
CTTCCAGCTTTGACTTCAATGGGCCCTACCTGGGGCCGCCCCACAGCCGCTCCCTACCTGACATCCTGGG
CCAGCCGGAGCCCCCACAGGAGGGTGGGAGCCAGAAGTCCCCACCTCCAGGGTCCCTGGAGTACCTGTGT
CTGCCTGCTGGGGGGCAGGTGCAACTGGTCCCTCTGGCCCAGGCGATGGGACCAGGACAGGCCGTGGAAG
TGGAGAGAAGGCCGAGCCAGGGGGCTGCAGGGAGTCCCTCCCTGGAGTCCGGGGGAGGCCCTGCCCCTCC
TGCTCTTGGGCCAAGGGTGGGAGGACAGGACCAAAAGGACAGCCCTGTGGCTATACCCATGAGCTCTGGG
GACACTGAGGACCCTGGAGTGGCCTCTGGTTATGTCTCCTCTGCAGACCTGGTATTCACCCCAAACTCAG
GGGCCTCGTCTGTCTCCCTAGTTCCCTCTCTGGGCCTCCCCTCAGACCAGACCCCCAGCTTATGTCCTGG
GCTGGCCAGTGGACCCCCTGGAGCCCCAGGCCCTGTGAAGTCAGGGTTTGAGGGCTATGTGGAGCTCCCT
CCAATTGAGGGCCGGTCCCCCAGGTCACCAAGGAACAATCCTGTCCCCCCTGAGGCCAAAAGCCCTGTCC
TGAACCCAGGGGAACGCCCGGCAGATGTGTCCCCAACATCCCCACAGCCCGAGGGCCTCCTTGTCCTGCA
GCAAGTGGGCGACTATTGCTTCCTCCCCGGCCTGGGGCCCGGCCCTCTCTCGCTCCGGAGTAAACCTTCT
TCCCCGGGACCCGGTCCTGAGATCAAGAACCTAGACCAGGCTTTTCAAGTCAAGAAGCCCCCAGGCCAGG
CTGTGCCCCAGGTGCCCGTCATTCAGCTCTTCAAAGCCCTGAAGCAGCAGGACTACCTGTCTCTGCCCCC
TTGGGAGGTCAACAAGCCTGGGGAGGTGTGTTGA
Formulation: Lentivector encoded and pre-packaged viral particles (typical titer 106 - 107 IFU/ml) in the conditional medium (serum-free) from HEK293 cells that have been transfected with the lentivector gene clone and the LentiPAK DNA mix
FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.
Important Safety Information: With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.
Restriction: This product is not transferable or re-sellable. Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose. Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules. Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction. Your use of this product constitutes acceptance of the terms of this limited use agreement. Please refer to our “terms & conditions” for details. If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.
Pre-packaged lentiviral particles are most advanced gene delivery tools. Each particles contain a fully sequence verified target gene and are psudotyped with the VSV-G glycoprotein, ready for transduction into into a wide range of cell types including hard-to-transfect primary cells and non-dividing cells. They are supplied in 1-mL aliquot(s) of the serum-/antibiotic-free solution suitable for both in vitro and in vivo delivery. They are produced in HEK293 packaging cells with a typical titer of ≥107 IFU/ml using our optimized LentPAKTM packaging system. The lentiviral particles can be used to transduce subconfluent target cells. Depending on your purpose, you may choose a specific multiplicity of infection (MOI) or test a range of MOIs to determine which gives you the desired results. Transduction can be enhanced by the addition of polybrene, also known as hexadimethrine bromide (typically at 8-10 μg/ml).
Quick Protocol for Transduction
Day 1. Seeding Target Cells
For an example, plate target cells in a 10 cm plate at a density of 1 - 5x 105 cells/ml that will produce approximately 60% confluency in 24 hours.
Note: other size plates can also be used depending on the nature of your experiment. Adjust the reagent amount according to Table 1
Table 1. Seeding Density of Target Cells (1 day prior to transduction)
Vessel Type |
Seeding Density |
Volume of Media |
10-cm dish |
1 – 5 x 106 |
10 mL |
6-well plate |
0.3 – 1 x 106 |
2 mL/well |
12-well plate |
0.15 – 0.5 x 106 |
1 mL/well |
24-well plate |
0.6 – 2 x 105 |
0.5 mL/well |
96-well plate |
1 – 4 x 104 |
0.1 mL/well |
Day 2. Transduction
Remove the growth media from the dish/plate prepared the day before. Replace with 1/2 volume of culture medium containing desired amount of lentiviral particles (at 2 to 20 MOI). For example, add 4.5 mL of growth medium and 0.5 mL of Lentiviral particles, or simply add 5 mL of Lentiviral particles (for a low titer viral preparation or a high MOI transduction). Add polybrene directly to the media on the target cells at 8 μg/ml. Mix by gentle swirling.
Incubate at 37°C with 5% CO2 for 4 - 24 hours, then replace the transduction medium with right amount of growth medium according to table 1 (for example 10 mL for 10-cm dish). Culture the cells for 48 – 72 hours, and transduced cells are ready for downstream analyses.
Note: Adjust volumes accordingly for transduction of other plate types. For example, add 1 ml of growth medium and lentiviral particle mixture for 6-well plate, 0.5 ml for 12-well and 0.25 mL for 24-well except for 96 well, in which 100 μl should be used. The change of transduction medium is often unnecessary with our pre-packaged lentiviral particles. Simply culture cells for 3-4 days before analysis.
The virus-containing media can be changed in as short as 4 hours after transduction if toxicity of the lentiviral transduction is a concern. Normally reverse transcription and genome integration of the lentivector takes place within 24-36 hours. With our ready-to-use, prepackaged lentiviral particles, the change of media is often unnecessary. The transduction process can be ongoing for 2 - 6 days without significant impact on cell growth/viability. The transduction process can also be repeated if desired. For a lentivector with a fluorescent reporter (such as GFP), FACS can be used to enrich for cells that express GFP. If it contains a drug selectable marker, follow the protocol for the particular drug. For example, puromycin selection is usually carried out at 1-10 μg/mL, depending on the target cells’ sensitivity
Important Safety Information
With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.
FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.
1. Proc. Natl. Acad. Sci. 87:9655 (1990)
2. J. Clin. Invest. 100:2211-2217(1997)
3. J. Mol. Biol. 297:989-1001(2000)
4. Cell 104:291-300(2001)
5. J. Med. Genet. 48:205-209(2011)
Additional supporting documents, including Product data sheet (PDS), COA and MSDS are available upon request.
FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.
Restriction: This product is not transferable or re-sellable. Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose. Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules. Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction. Your use of this product constitutes acceptance of the terms of this limited use agreement. Please refer to our “terms & conditions” for details. If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.
Earn discounts, credits or rewards with your purchases.
Get the sequence-verified, expression-ready gene clones.
Oder your high-quality, recombinant proteins of interest.
Try our products & services for your antibody R&D.
Acquire high titer, ready-to-use viral particles.
Send your question or feedback on our products & services